In this CE activity, expert faculty discuss the rationale for targeting tyrosine kinases as well as the latest clinical data on emerging TKIs for the management of patients with retinal diseases.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/retinacme/miscellaneous-macular-diseases/20241231/in-case-you-missed-the-promise-of-tyrosine-kinase-inhibitors-in-the-treatment-of-retinal-disease/overview
- Start Date: 2024-12-31 06:00:00
- End Date: 2024-12-31 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: Ocular Therapeutix, Inc. - Amount: 57472.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest